Skip to content
Study details
Enrolling now

Cannabidiol (CBD) in Adults With ASD

Johns Hopkins University
NCT IDNCT05015439ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

40

Study length

about 3.7 years

Ages

18+

Locations

1 site in MD

What this study is about

Researchers are testing whether cannabidiol (CBD), a treatment, can help adults with autism spectrum disorder (ASD) who have anxiety, mood problems, sleep issues, and agitation. The trial will last 14 weeks, with participants receiving either CBD or a placebo pill for six weeks each, followed by two weeks without medication. Participants will be asked about their symptoms and daily functioning during it.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cannabidiol
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cannabidiol

Drug routes

oral (Oral Solution)

Endpoints

Secondary: Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale, Change in Mini Mental State Examination (MMSE), Change in Waisman Activities of Daily Living scale

Body systems

Psychiatry / Mental Health